This author has yet to write their bio.Meanwhile lets just say that we are proud Haley Chartres contributed a whooping 45 entries.
Australian medicinal cannabis revenue is tipped to double this year amid growing confidence in the emerging sector. And WA is poised to maintain a significant hold of the market share. While the State is recognised globally for its optimal growing conditions, local cultivators, manufacturers and researchers have also benefited from limited COVID-19 interference in their […]
Papulopustular rosacea is a highly visible and distressing chronic inflammatory skin disease characterised by intensely inflamed skin and acne-like breakouts across the face – and new therapies are in demand. Botanix has today announced that we have received ethics approval for our BTX 1702 Phase 1b clinical study for the treatment of papulopustular rosacea, together […]
The Australian Government has published the Final Progress Report for Australia’s First National Antimicrobial Resistance Strategy 2015–2019 detailing its efforts to limit the incidence of antimicrobial resistance (AMR) in Australia. The report highlights activities implemented between 2017 and 2019 in the human and animal health, food production and the environment. Looking ahead, the Australian Government […]
Botanix Pharmaceuticals President and Executive Chairman, Vince Ippolito, presented at the ASX Small and Mid-Cap Conference today. View the presentation here:
Article extract | “Novartis’ acquisition represents a double-down on an antibiotics field facing an existential crisis from resistant “super bugs” that have sent most major drugmakers running for the hills — including Novartis, which dumped its antibiotic R&D program in 2018. But adding ever-greater volume to their generic antibiotics portfolio could offer Novartis some bottom-line […]
‘A huge acquisition in the international medical cannabis sector is set to give tailwinds to several ASX-listed marijuana companies, Scott Power says. Ireland-based Jazz Pharmaceuticals (NASDAQ:JAZZ) this week agreed to buy cannabinoid drugmaker GW Pharmaceuticals (NASDAQ:GWPH) for $US7.2 billion ($9.4 billion) – a 50 per cent premium to GW’s closing price on Tuesday.’ Click through to read the full article […]
GW Pharma $GWPH, the UK biotech that caused a sensation of sorts with the approval of the world’s first cannabinoid med, is being bought out. Jazz Pharmaceuticals came up with the winning number, agreeing to acquire GW for a total of $7.2 billion — $6.7 billion net of cash. GW agreed to a price of […]
‘The Botanix Pharmaceuticals (ASX:BOT) share price has returned from its trading halt with a bang on Wednesday. In morning trade, the clinical stage synthetic cannabinoid company’s shares are up 31% to a record high of 19 cents.’ Click through to read the full article on The Motley Fool.
‘Botanix Pharmaceuticals (ASX:BOT) shares have soared after a small clinical trial backed the feasibility of putting synthetic cannabis up the nose of surgical patients to prevent infections. While cannabis is of course mostly known for its psychoactive properties, a number of companies trying to unlock its therapeutic benefit and Botanix’s research has shown that cannabidiol (CBD) is […]
Philadelphia PA and Sydney Australia, 3 February 2021: Clinical stage synthetic cannabinoid company Botanix Pharmaceuticals Limited has today published positive data from a world first human clinical study, examining the safety, tolerability and efficacy of its BTX 1801 antimicrobial product for the eradication of Staphylococcus Aureus (Staph). Staph, also called golden staph, is a common […]
AUSTRALIA
Level 1, 50 Angove Street, North Perth WA 6006
USA
3602 Horizon Drive, Suite 160, King of Prussia, PA 19406
Be notified of important news from Botanix.
AU +61 8 6555 2945
US + 1 445 300 3403
info@botanixpharma.com